Niemann-Pick type C (NPC) disease, an autosomal recessive disorder caused primarily by loss-of-function mutations in NPC1 gene, is characterized neuropathologically by intracellular cholesterol accumulation, gliosis and neuronal loss in selected brain regions. Recent studies have shown that NPC disease exhibits intriguing parallels with Alzheimer's disease (AD), including the presence of tau-positive neurofibrillary tangles (NFTs) and b-amyloid (Ab)-related peptides in vulnerable brain regions. Since enhanced cholesterol level, which acts as a risk factor for AD, can increase Ab production by regulating amyloid precursor protein (APP) metabolism, it is possible that APP overexpression can influence cholesterol-regulated NPC pathology. We have addressed this issue in a novel bigenic mice (ANPC) generated by crossing heterozygous Npc1-deficient mice with mutant human APP transgenic mice. These mice exhibited decreased lifespan, early object memory and motor impairments, and exacerbated glial pathology compared with other littermates. Neurodegeneration observed in the cerebellum of ANPC mice was found to be accelerated along with a selective increase in the phosphorylation/cleavage of tau protein. Additionally, enhanced levels/activity of cytosolic cathepsin D together with cytochrome c and Bcl-2-associated X protein suggest a role for the lysosomal enzyme in the caspase-induced degeneration of neurons in ANPC mice. The reversal of cholesterol accretion by 2-hydroxypropyl-b-cyclodextrin (2-HPC) treatment increased longevity and attenuated behavioral/pathological abnormalities in ANPC mice. Collectively, our results reveal that overexpression of APP in Npc1-deficient mice can negatively influence longevity and a wide spectrum of behavioral/neuropathological abnormalities, thus raising the possibility that APP and NPC1 may interact functionally to regulate the development of AD and NPC pathologies.
INTRODUCTION
Niemann-Pick type C (NPC) disease is an autosomal recessive neurovisceral disorder characterized by abnormal accumulation of unesterified cholesterol and glycosphingolipids within the endosomal-lysosomal (EL) system in a number of tissues including the brain. These defects in cholesterol sequestration trigger widespread neurological deficits such as ataxia, seizures and dementia that eventually lead to premature death (1, 2) . In majority of the cases, NPC disease is caused by loss-of-function mutations in the NPC1 gene, which encodes a transmembrane glycoprotein implicated in the intracellular transport of cholesterol (3, 4) . Neuropathologically, NPC is characterized by the accumulation of unesterified cholesterol, activation of glial cells and presence of intracellular taupositive neurofibrillary tangles (NFTs). Loss of neurons is evident primarily in the prefrontal cortex, thalamus and cerebellum but not in the hippocampus (5, 6) . Some studies have also shown that levels of b-amyloid (Ab)-related peptides are increased in the vulnerable brain regions (7) as well as in the cerebrospinal fluid (8) , while extracellular deposition of the peptide was apparent in patients with 14 genotype of * To whom correspondence should be addressed at: Centre for Prions and Protein Folding Diseases, Departments of Medicine (Neurology) and Psychiatry, University of Alberta, Edmonton, AB T6G 2M8, Canada. Tel: +1 780 492 9357; Fax: +1 780 492 9352; E-mail: skar@ualberta.ca apolipoprotein E (APOE), which serves as a protein carrier for cholesterol (9) . Interestingly, Balb/cNctr-Npc N/N mice due to spontaneous mutations in the Npc1 gene (Npc-null) are found to recapitulate most of the human pathology, except for the formation of NFTs (10, 11) .
A number of recent studies have shown that NPC disease exhibits some intriguing parallels with the Alzheimer's disease (AD), the most common type of senile dementia affecting the elderly people. Neuropathologically, AD is characterized by the presence of NFTs, Ab-containing neuritic plaques, gliosis and the loss of neurons primarily in the hippocampus, cortex and certain subcellular nuclei such as basal forebrain cholinergic neurons (12) (13) (14) . The pathological changes observed in AD brains are believed to be triggered by in vivo accumulation of Ab peptides derived from amyloid precursor protein (APP). The AD pathology, unlike NPC disease, is not associated with widespread intracellular accumulation of free cholesterol or loss of neurons in the cerebellum. Additionally, development of AD which occurs mostly after 65 years of age does not lead to ataxia as observed in NPC disease (2, 6, 13, 14) . Notwithstanding the differences, the striking parallels that exist between AD with NPC include (i) the presence of structurally and immunologically similar tau-positive NFTs (15, 16) , (ii) influence of 14 isoform of APOE in promoting disease pathology (9, 17, 18) and (iii) endosomal abnormalities associated with accumulation of cleaved APP and/or Ab peptides in vulnerable neurons (19) . Recently, alteration of NPC1 mRNA/ protein has been reported in vulnerable regions of AD brains indicating a functional link between NPC1 dysfunction and AD (20) . Although cholesterol is not sequestered in AD as observed in NPC pathology, there is evidence that high cholesterol level increases the risk of AD (21, 22) and neurons bearing NFTs exhibit higher levels of free cholesterol in AD brains (23) . Many lines of experimental evidence further suggest that alteration in cholesterol homeostasis can influence APP metabolism, whereas changes in the level/expression of APP can also lead to altered cholesterol metabolism (24) (25) (26) (27) . These results albeit promote convergence of factors regulating NPC and AD pathologies, very little is currently known about the interaction between the NPC1 and APP.
Transgenic mice overexpressing mutant APP are known to recapitulate amyloid deposits and spatial learning deficits but do not exhibit overt loss of neurons as seen in AD brains (28) (29) (30) (31) . Earlier studies have shown that the up-regulating cholesterol level can exacerbate behavior and cellular pathology, whereas the decreasing cholesterol level can have opposite effects in these mice (24, 27) . However, it remains unclear how APP overexpression can influence behavior and pathological features, particularly the tau pathology and neurodegeneration that lie downstream of altered APP and cholesterol metabolisms, in Npc-null mice. We addressed this issue by using a new line of bigenic ANPC mice generated by crossing mutant human APP transgenic mice (29) with heterozygous Npc1-deficient mice (32) . Our results clearly show that overexpression of APP in the presence of intracellular cholesterol accumulation can decrease longevity, accelerate the onset of behavioral abnormalities and exacerbate glial pathology as well as degeneration of neurons that show preferential vulnerability to cholesterol accumulation in NPC disease. To establish the significance of cholesterol, we treated ANPC mice with the sterol binding agent 2-hydroxypropyl-b-cyclodextrin (2-HPC) that has been shown to promote movement of the sequestered cholesterol from lysosomes to the metabolically active pool in various experimental paradigms (33) (34) (35) . Our results clearly reveal that dispersal of cholesterol by 2-HPC treatment can not only prolong the lifespan but also can significantly reverse the behavioral and pathological abnormalities in ANPC mice, thus providing a strong functional link between APP and NPC1 genes that may interact in regulating both AD and NPC pathologies.
RESULTS

Generation of bigenic ANPC mice
To determine how overexpression of APP can influence pathological changes triggered by intracellular accumulation of cholesterol, we generated a novel bigenic ANPC mouse line (APP-Tg and Npc-null: APP
Npc1
2/2 ) by crossing mutant human APP transgenic (APP-Tg: APP
+/+ ) with heterozygous Npc1-deficient (APP 0/0 Npc1 +/2 ) mice (Fig. 1A ). Our immunoblotting analysis revealed that APP holoprotein levels in ANPC mice were similar to APP-Tg and double heterozygous (Dhet: APP
+/2 ) mice but were markedly higher compared with wild-type (WT: APP 0/0 Npc1 +/+ ) and homozygous Npc-null mice (Npc-null: APP 0/0 Npc1 2/2 ), as expected (Fig. 1B) . Npc1 protein levels did not differ between WT and APP-Tg mice, and as anticipated, the Dhet mice showed 50% reduction, while Npc-null and ANPC mice did not exhibit detectable levels of this protein (Fig. 1B) . ANPC mice had a maximum of 77-day lifespan, with the mortality rate increasing drastically from the 55 days onward (Fig. 1C) . Npc-null mice, as reported earlier (36) , exhibited a reduced lifespan with only 30% of the animals alive past the 90-day censor date in our colony. The majority (.90%) of APP-Tg and Dhet mice, on the other hand, survived past the censor date, whereas the WT mice had no recorded deaths within the study period. Thus, the bigenic ANPC mice had a significantly reduced lifespan compared with WT, APP-Tg, Dhet or Npc-null mutants (Fig. 1C) . Additionally, the ANPC mice reached a maximum body weight of 12 g by 6 weeks, which was 30% less compared with other lines of mice, and then declined progressively until death (Fig. 1D ).
Accelerated object recognition memory and motor deficits
To determine whether overexpression of APP in Npc-null mice can influence cognitive performance, we evaluated all five genotypes at 4, 7 and 10 weeks of age in an object recognition memory test (Fig. 2A) . The performance of WT, APP-Tg, Dhet, Npc-null and ANPC mice did not differ significantly at 4 weeks of age (data not shown). The ANPC mice, however, exhibited significant deficits in the object memory index (MI) at 7 and 10 weeks, whereas APP-Tg, Dhet and Npc-null mice showed a reduced MI only at 10 weeks ( Fig. 2A) . Loss of Npc1 function is known to impair motor ability in Npc-null mice (37) . To examine this effect, we first tested mice of all five genotypes at 4, 7 and 10 weeks of age for their spontaneous locomotor activity (walking, rearing and periods of inactivity) in open-field tests showing the average latency to fall from an accelerating rotarod for WT, APP-Tg, Dhet, Npc-null and ANPC mice at 7 and 10 weeks of age. ANPC mice exhibited significant motor impairment at 7 weeks, which progressively worsened by 10 weeks. Npc-null mice exhibited significant motor impairment only at 10 weeks, whereas APP-Tg and Dhet mice did not display any impairment at either 7 or 10 weeks of age. Data are expressed as means + SEM of all trials performed on the final test day, with n ¼ 6-10 for each genotype. (C) Histograms showing alternation coefficients representing gait asymmetry in all five genotypes of mice as assessed by measurement of the right hind paw stride length. The WT, APP-Tg and Dhet mice exhibited a normal alternating gait at both 7 and 10 weeks of age. The ANPC mice showed severe gait abnormalities at 7 and 10 weeks of age, whereas Npc-null mice displayed gait disturbances only at 10 weeks. Data are expressed as means + SEM of alternation coefficients, with n ¼ 6 -10 for each genotype. * P , 0.05. Fig. S1A -C) . No significant variation was apparent in the sensorimotor behavior between the genotypes at 4 weeks of age (data not shown). The ANPC mice exhibited significantly reduced locomotor activity and increased periods of inactivity in our open-field tests at both 7 and 10 weeks age, whereas Npc-null mice showed these deficits mostly at the later age of 10 weeks only. The APP-Tg and Dhet mice did not show any difference from WT at any age (Supplementary Material, Fig. S1A -C) . Furthermore, rotarod performance and gait coordination analysis revealed that motor coordination in Npc-null mice was impaired at 10 weeks but not at 4 or 7 weeks of age. The ANPC mice, on the other hand, displayed a significant impairment in their motor function at 7 weeks, which was further exacerbated by 10 weeks. The APP-Tg and Dhet mice did not show any motor deficit compared with WT mice at any age ( Fig. 2B and C).
Intracellular accumulation of unesterified cholesterol
We 
Aggravated glial activation and demyelination
At the cellular level, ANPC mice showed a profound increase in the number and activation of glial fibrillary acidic protein (GFAP)-labeled astrocytes in both the hippocampus and cerebellum compared with WT, APP-Tg, Dhet and Npc-null mice ( Fig. 3A -J) . Our western blot analysis also revealed a significant increase in GFAP levels in the hippocampus and cerebellum of 4, 7 and 10 weeks old ANPC mice compared with WT, APP-Tg and Dhet mice ( Fig. 3K and L) . The Npc-null mice displayed a significant increase in GFAP levels over the WT, APP-Tg and Dhet mice, mostly at later stages. The relative increase in ANPC over Npc-null mice was evident at 4 weeks but not at later stages. Consistent with the alteration in astrocytes, ANPC mice showed profound microglial activation in both the hippocampus and cerebellum compared with all other genotypes ( In contrast, the ANPC mice showed numerous intensely stained phagocytic, amoeboid microglia microglia were apparent in the cerebellum ( Fig. 4E and J). Agematched Npc-null mice, on the other hand, revealed less activated microglia in both the hippocampus and cerebellum than those observed in ANPC mice ( Fig. 4D and I). Our western blot analysis also showed a significant increase in Iba1 levels in the hippocampus and cerebellum of 4, 7 and 10 week old ANPC mice compared with WT, APP-Tg and Dhet mice ( Fig. 4K and L). The increase over the Npc-null mice was evident only in 4 weeks cerebellum. Interestingly, the relative increase in Iba1 levels was found to be more profound in the cerebellum than the hippocampus of ANPC and Npc-null mice compared with the other lines of mice.
Immunohistochemical staining with the oligodendrocyte marker 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) showed a dramatic loss of myelin fibre tracts in the ANPC hippocampus/cortex and cerebellum compared with the other lines of mice ( Fig. 5A-J ). This was substantiated by our western blot data, showing striking decreases in CNPase levels in ANPC hippocampus and cerebellum at 4, 7 and 10 weeks ( Fig. 5K and L). Npc-null mice, as reported earlier (38) , also showed significant demyelination at various ages, but this was found to be less severe than ANPC mice at earlier stages. Additionally, the levels of CNPase in the hippocampus, but not in the cerebellum, were depleted in APP-Tg and Dhet mice at later stages compared with age-matched WT mice ( Fig. 5K and L).
Loss of neurons and synaptic markers
Our APP-Tg mice, as reported for most other lines of mutant APP mice, do not exhibit frank loss of neurons in any brain region (28, 29) . The Npc-null mice, on the other hand, show a progressive loss of neurons in selected brain regions such as thalamus and cerebellum but not in the hippocampus (5, 6) . In keeping with these results, we observed a significant decrease in the number of cerebellar Purkinje cells in ANPC and Npc-null mice compared with WT, APP-Tg and Dhet mice ( Fig. 6A -L) . The magnitude of cell loss was found to be more pronounced in ANPC than in the Npc-null mice ( 
Activation of tau kinases and phosphorylation of tau
Although florid tau pathology is not apparent in either APP-Tg or Npc-null mice, there is evidence that altered cholesterol levels can regulate tau phosphorylation under in vitro conditions (39) . To determine whether overexpression of APP together with intracellular cholesterol accumulation can influence tau phosphorylation under in vivo paradigm, we first evaluated tau kinases in all lines of mice. Our results clearly demonstrated a significant up-regulation of phospho-extracellular signalregulated kinase 1/2 (ERK1/2) in the cerebellum, but not in the hippocampus, of Npc-null or ANPC mice ( Fig. 7A -D) . Additionally, the steady-state levels of p35 were found to be decreased in the cerebellum, but not hippocampus, of Npc-null and ANPC mice compared with other lines of mice ( Fig. 7A -D) . In contrast, the levels of phospho-glycogen synthase kinase-3b (GSK-3b) did not alter in the ANPC or Npc-null mice (Supplementary Material, Fig. S4A and B) . As a follow-up, we measured the levels of total tau using Tau-1 and Tau-5 antibodies and phospho-tau using various epitope specific antibodies in the hippocampus and cerebellum of five different lines of mice ( Fig. 8A-D) . Our results clearly showed that the total-tau level was strikingly decreased in the cerebellum, but not hippocampus, of ANPC and Npc-null mice compared with other lines. Interestingly, the levels of phospho-tau remain unaltered in both brain regions of ANPC and Npc-null mice with respect to other genotypes. Thus, it is evident that phosphorylation of tau is selectively increased in the affected cerebellar region, which was more pronounced in ANPC than Npc-null mice. More recently, a number of studies have indicated that proteolytic cleavage of tau protein, in addition to enhanced phosphorylation, may have a role in the degeneration of neurons (40) (41) (42) . Our results showed that levels of caspasecleaved tau are markedly increased in the cerebellum, but not hippocampus, of the ANPC and Npc-null mice ( Fig. 8A-D) . The relative change, however, was more obvious in ANPC than Npc-null mice. At the cellular level, cleaved tau immunoreactivity was evident only in the Purkinje cells of the ANPC and Npc-null mice but not in WT, APP-Tg or Dhet mice ( Fig. 8E-G) .
Increased activity and cytosolic levels of cathepsin D
Several studies have shown that up-regulation of lysosomal enzymes within lysosomes can prevent sub-lethal damage (43) , whereas lysosomal rupture leading to sustained release of enzymes into the cytosol can induce cell death via cytochrome c release from mitochondria (44) (45) (46) . To determine the potential involvement of the lysosomal enzymes in ANPC mice, we measured the level/activity and subcellular distribution of cathepsin D in all five lines of mice ( Fig. 9A-F ; 
4864
Human
Supplementary Material, Fig. S5A and B) . Our results clearly showed that cathepsin D levels and activity were significantly higher in the hippocampus and even more pronounced in the cerebellum of ANPC and Npc-null mice compared with other lines of mice (Fig. 9A-D) . It is of interest to note that the activity of this enzyme was found to be increased more profoundly in ANPC cerebellum compared with Npc-null mice (Fig. 9D) . Our subcellular fractionation results further revealed that cytosolic cathepsin D levels were higher in the cerebellum of ANPC and Npc-null mice compared with WT mice (Fig. 9F ).
Similar to cathepsin D, the levels of cytochrome c and Bcl-2-associated X protein (Bax), but not apoptosis inducing factor (AIF), were increased in the cerebellar cytosolic fraction of ANPC and Npc-null mice compared with other lines (Fig. 9F,  Supplementary Material, Fig. S5B ). The relative change was found to be more obvious in the ANPC than Npc-null mice (Fig. 9F) . In contrast to the cerebellum, alterations in hippocampal cytosolic cathepsin D, cytochrome c and Bax levels were less apparent in ANPC and Npc-null mice compared with WT mice (Fig. 9E, Supplementary Material, Fig. S5A ). It is also of interest Fig. S5A and B).
Effect of 2-HPC treatment
To determine whether lowering cholesterol accumulation can attenuate the aforementioned abnormalities, we injected WT, Npc-null and ANPC mice with 2-HPC or saline at postnatal day 7 and then evaluated their behavioral and pathological (Fig. 10A) . Additionally, our results clearly showed that 2-HPC treatment can lead to significant improvement in the motor and cognitive performances of 7-week-old ANPC and Npc-null mice compared with the respective saline-treated genotypes ( Fig. 10B and C) .
At the cellular level, we observed that 2-HPC treatment was able to sequester filipin-labeled cholesterol accumulation in most neurons in 4-week old ANPC and Npc-null mice ( Fig. 11A -H) . Accompanying these changes, the number of surviving Purkinje cells in treated ANPC and Npc-null mice, albeit significantly lower than WT mice, was found to be doubled compared with the saline-injected ANPC and Npc-null mice ( Fig. 12A-E) . Our immunohistochemical analysis further showed a significant decrease in the activation of GFAP-labeled astrocytes and Iba1-labeled microglia in both the hippocampus and cerebellum of 2-HPC-treated ANPC and Npc-null mice compared with the respective saline-treated animals ( Fig. 13A-P) . The beneficial effects of 2-HPC were also reflected with a substantial increase in CNPase immunoreactivity, suggesting preservation of brain myelination (Fig. 13Q-X) . More interestingly, 2-HPC treatment, as evident from our western blot analysis, markedly attenuated the enhanced levels of phospho-ERK1/2 in the cerebellum of ANPC and Npc-null mice (Fig. 14A and B) . This was accompanied by a parallel increase in total-tau and a decrease in cleaved tau levels in the cerebellum of 2-HPC-treated ANPC and Npc-null animals compared with the respective saline-injected genotypes (Fig. 15A and B) . Histograms showing that 2-HPC treatment significantly improved the performance of Npc-null and ANPC mice in 3-h object recognition memory (B) and rotarod (C) tests compared with their respective saline-treated control groups but had no effect on the WT animals. The values are expressed as means + SEM, with n ¼ 6 -10 for each group.
* P , 0.05. 
DISCUSSION
Using a new line of bigenic ANPC mice, the present study shows that overexpression of APP in the absence of functional Npc1 protein can significantly decrease longevity, impair motor and object recognition memory functions, exacerbate glial pathology and accelerate degeneration of neurons. This is accompanied by altered function of the EL system and increased phosphorylation and cleavage of tau protein. Neuropathological abnormalities are more profound in the cerebellum, exhibiting a significant loss of neurons than the relatively spared hippocampus in ANPC mice. This is supported by the results which showed that (i) proliferation of astrocytes and microglia and loss of myelin are notably higher in the cerebellum than the hippocampus, (ii) phosphorylation and cleavage of tau protein are selectively enhanced in the cerebellum and (iii) cytosolic levels of cathepsin D, cytochrome c and Bax are increased more predominantly in the cerebellum than the hippocampus. It is also of interest to note that cerebellar dysfunctions in ANPC mice are conspicuously more severe than in Npc-null, Dhet, APP-Tg and WT mice. Reversal of accumulated cholesterol by 2-HPC treatment not only prolongs the lifespan but also attenuates behavioral and glial pathology in ANPC mice. This is accompanied by enhanced survival of neurons and decreased phosphorylation/cleavage of tau protein. Collectively, these results suggest that overexpression of APP in the Npc-null mice can influence longevity as well as a wide spectrum of behavioral and neuronal abnormalities associated with NPC disease, whereas reversal of cholesterol accumulation is beneficial in attenuating these abnormalities. Multiple lines of evidence have shown that elevated cholesterol levels can influence APP metabolism as well as AD-related pathology (47) . Conversely, APP-Tg mice exhibit altered levels of lipids surrounding plaque cores that may have a role in the dynamic of amyloid aggregation (48) . The present study clearly reveals that APP overexpression did not elicit any obvious alterations either on intracellular accumulation or total levels of cholesterol in Npc-null mice. This could possibly reflect a compensatory adjustment where increased cholesterol levels in the cell bodies are obscured by its reduction in myelin, the major repository of cholesterol in the central nervous system (26) . Overexpression of APP, however, drastically reduces the lifespan of Npc-null mice along with a progressive decline in their body weight. This is interesting in the context of the results, which showed that decreasing de novo cholesterol synthesis/turnover by deleting the 24-hydroxylase gene can prolong the lifespan of APP-Tg mice (49) . Accompanying the mortality rate, object recognition memory and a spectrum of sensorimotor functions including locomotor activity and gait coordination are impaired earlier in ANPC mice than in Npc-null, APP-Tg, Dhet and WT mice. Given the evidence that all these mice were generated on the same outbred genetic background, the behavioral changes observed in ANPC mice most likely reflect the influence of APP overexpression in the context of an Npc-null genotype, rather than the coincident segregation of (hypothetical) modifier genes. Prior studies have reported motor impairments in the Npc-null mice (37) and object memory deficits in APP-Tg mice without any evidence of motor dysfunction (30) . Our results, however, reveal that overexpression of APP induces early motor and object memory deficits in Npc-null mice compared with other littermates. While object memory relies on the integrity of entorhinal-hippocampal circuitry (50), the cerebellum is known to play a critical role in regulating normal motor activity (51, 52) . The early manifestation of behavioral deficits in ANPC Earlier studies have shown activation of both astrocytes and microglia in APP-Tg and Npc-null mice, but loss of myelin only in Npc-null mice (5, 10, 53) . The overall glial pathology in ANPC mice is markedly exacerbated at the earlier stages compared with other littermates, whereas at the later stages it varies from other genotypes except Npc-null mice. This suggests that APP overexpression may induce early glial activation in Npc-null mice which can subsequently influence disease pathology. This is partly reflected in the loss of cerebellar Purkinje cells which is more severe in ANPC than in Npc-null mice. Interestingly, hippocampal neurons, even though accumulate cholesterol, are found to be relatively spared in ANPC mice as observed in Npc-null mice. It is possible that these neurons are being protected against toxic insults by an up-regulation of survival mechanisms as demonstrated in mutant APP-Tg mice (54) or they might be vulnerable if the animals would have lived longer.
Most APP-Tg mice do not exhibit any overt loss of neurons, but there is evidence that defective steroidogenesis (55), abnormal lipid trafficking (56) and production of inflammatory molecules (10) from glia can negatively affect NPC disease progression and neuronal viability. This is supported by the observation that an astrocyte-targeted Npc1 transgene can enhance lifespan and decrease neurodegeneration in Npc-null mice (57). However, two independent studies using a mouse chimera (58) or a conditional knock-out of Npc1 (51) have demonstrated cell autonomous death of Purkinje neurons. Additionally, neuron-targeted Npc1 gene expression was able to protect neurons and prolonged lifespan in Npc-null mice (59) , suggesting that the loss of Npc1 function in neurons rather than glia may be responsible for the loss of neurons in ANPC mice.
At present, the precise mechanism that may underlie degeneration of neurons in either AD or NPC brain remains unclear, but there is evidence of up-regulation of lysosomal enzymes in 'at-risk' neurons in both the diseases (7, 60) . This is substantiated by our study, which shows an increased level and activity of the cathepsin D both in the hippocampus and cerebellum of ANPC and Npc-null mice. Our subcellular data, on the other hand, show that cytosolic levels of cathepsin D are markedly increased in the cerebellum, but only slightly increased in the relatively spared hippocampus of Npc-null and ANPC mice compared with WT controls. This is accompanied by a parallel increase in the cytosolic levels of cytochrome c and Bax in the cerebellum of Npc-null and ANPC mice. The magnitude of cytosolic cathepsin D levels, in keeping with the loss of neurons, is found to be markedly higher in ANPC than Npc-null mice. There is evidence that increased activity of enzymes within lysosomes or limited release of enzymes into the cytosol can prevent sub-lethal damage, whereas sustained release of the enzymes into the cytosol can induce cell death (43, 45) . Thus, it is likely that enhanced levels of cathepsin D in the hippocampus may counter cellular abnormalities resulting from APP overexpression/cholesterol accumulation or may not reach levels necessary to mediate cell death. On the other hand, larger increases in cytosolic levels of the enzyme in the cerebellum, resulting from lysosomal destabilization, may lead to death of neurons. This is supported by two lines of evidence: (i) Purkinje cells, but not hippocampal neurons, are labeled with cleaved caspase-3 in ANPC and Npc-null mice and (ii) cytosolic cathepsin D levels did not differ in hippocampus or cerebellum among APP-Tg, Dhet and WT mice, which do not exhibit any loss of neurons. Apart from lysosomal dysfunction, the presence of taupositive NFTs represents a striking similarity between AD and NPC pathologies (15, 16) . The formation of tangles resulting from phosphorylation of tau protein has been implicated in the degeneration of neurons in many taupathies including NPC and AD brains by triggering loss of microtubule binding and impaired axonal transport (61) . Tau phosphorylation is usually mediated in a site-specific manner by various kinases including ERK1/2, GSK-3b and Cdk-5 (62, 63) . Although tau is known to be phosphorylated in APP-Tg and Npc-null mice, there is no evidence of its association with the loss of neurons or tangle formation in any region of the brain (64) (65) (66) . Our results clearly show that while the total-tau levels are decreased, phospho-tau levels in relation to total tau are increased in the cerebellum but not in the hippocampus of ANPC and Npc-null mice. These changes are significantly higher in ANPC than Npc-null mice and are accompanied by an increase in phospho-ERK1/2 and a decrease in p35 levels. Since partial or complete loss of tau expression can reduce lifespan and exacerbate pathology in Npc-null mice (67) and inhibitors of Cdk-5 can attenuate tau phosphorylation as well as the phenotype in Npc-null mice (37, 68) , it is likely that alterations in the levels and phosphorylation of tau in the cerebellum of ANPC and Npc-null mice may be involved in the loss of Purkinje neurons. Additionally, we showed that caspase-cleaved tau levels are selectively increased and expressed in the Purkinje neurons of ANPC and Npc-null mice. Since truncated tau generated by caspases tends to assemble more rapidly into filaments than full-length tau (69, 70) and is able to trigger neurodegeneration by reducing the pool of full-length tau available for binding to microtubules (40) (41) (42) , it is likely that cleaved tau in ANPC and Npc-null mice may also contribute to the loss of Purkinje neurons.
Since neuropathological abnormalities in mutant ANPC mice were evident primarily in brain regions that are preferentially vulnerable to cholesterol accumulation in NPC pathology, we treated the animals with 2-HPC-which binds to cholesterol and facilitates its exit from lysosomes even in the absence of functional Npc1 protein (71) . A number of recent studies have shown that single or repeated administration of 2-HPC can increase lifespan, delay motor impairments and reduce neuronal cholesterol accumulation in Npc-null mice. Additionally, 2-HPC treatment is able to attenuate degeneration of neurons as well as glial pathology in Npc-null mice (33) (34) (35) 72) . Our results also clearly show that single systemic administration of 2-HPC at postnatal day 7 can not only prevent cholesterol accumulation but also prolong the lifespan and attenuate both motor and object recognition memory deficits in ANPC and Npc-null mice. Additionally, a marked reduction in the glial pathology and protection of Purkinje cells are apparent in 2-HPC-treated ANPC and Npc-null mice compared with the respective saline-treated mice. These cellular changes are accompanied by a significant reversal of phospho-ERK1/2 levels as well as phosphorylation and cleavage of tau in the cerebellum of ANPC and Npc-null mice. Given the beneficial effects of a single injection, it would be of interest to determine whether repeated injections of 2-HPC over time can completely prevent the dysfunction associated with ANPC mice. Nevertheless, our results clearly show that overexpression of APP in Npc-null mice can negatively influence longevity as well as a spectrum of behavioral and neuropathological features that can be reversed markedly by 2-HPC treatment. Additionally, this study raises the possibility of a functional interaction between APP and NPC1 that may have a role in the development of both AD and NPC diseases.
MATERIALS AND METHODS
Materials
Four to twenty percent Tris-Glycine gels, 4-12% NuPAGE BisTris gels, NeuroTrace red fluorescent Nissl stain (BrainStain TM Imaging Kit), Alexa Fluor 488/594 conjugated secondary antibodies and ProLong Gold antifade reagent were all purchased from Life technologies. The DNA isolation kit and Qproteome cell compartment kit were from Qiagen Inc. Filipin, the cathepsin D assay kit, and 2-HPC (product H107) were obtained from Sigma-Aldrich, Inc. The bicinchoninic acid (BCA) protein assay kit and the enhanced chemiluminescence (ECL) kit were obtained from ThermoFisher Scientific. Sources of all the primary antibodies used in the study are listed in Table 1 . All horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. All other chemicals were from Sigma-Aldrich or ThermoFisher Scientific.
Generation of transgenic mice
Mutant human APP KM670/671NL+V717F transgenic mice (APP-Tg) maintained on a C3H/C57BL6 background (29) were obtained from our breeding colony. Heterozygous Npc1-deficient (Npc1 +/2 ) mice (32) maintained on a BALB/ c background were purchased from Jackson Laboratories. Mutant APP-Tg mice were first crossed to Npc1 +/2 mice to produce APP +/0 Npc1 +/2 and APP 0/0 Npc1 +/2 off-springs. These two lines of mice were subsequently crossed to generate the following five lines of mice: bigenic APP +/0 Npc1 were bred and housed with access to food and water ad libitum. The probability of survival was determined by the Kaplan -Meier technique using GraphPad Prism software. The maintenance of the breeding colony and the experiments involving these animals were performed in accordance with Institutional and Canadian Council on Animal Care guidelines. All transgenic mice were identified by a unique ear notching pattern and genotyped by PCR analysis of tail DNA as described earlier (29, 32) .
Behavioral tests
WT, APP-Tg, Dhet, Npc-null and ANPC mice were examined at 4, 7 and 10 weeks of age for their object recognition memory and sensorimotor performance as described earlier (73) . All these mice were generated from the same breeding on a C3H/C57BL6/BALB/c background, thus making it likely that behavioral changes observed in any of these lines may be associated with altered expression of APP and/or Npc1 rather than with the background strains. For the object recognition memory test, mice were first habituated for five consecutive days and on the sixth day their exploratory behavior towards a familiar and novel object was quantified using a MI, wherein 't o ' represents the time exploring an object during the original exposure and 't n ' represents the time spent exploring an object that is novel on re-exposure:
The motor function of mice from different genotypes was tested by measurement of latency to fall from a Rotamex-5 accelerating rotarod (Columbus Instruments). All mice were examined 5 min each four times per day with an inter-trial interval of 30 min for five consecutive days. A score of 300 s was assigned to a mouse that stayed on the rod for the full 5 min test period. Gait analysis of the animals was done from their footprints as described earlier (74) . Stride lengths and hind limb widths were measured manually as the distance between two paw prints. Mice of different genotypes were also tested for their open-field activity over a 5-min test session. Durations of walking, pausing and rearing were analyzed as indices of spontaneous locomotor activity as described earlier (73) .
Cellular cholesterol assay
The hippocampus and cerebellum of 4-, 7-and 10-week mice of all five genotypes (n ¼ 4 per genotype/age group) were homogenized and mass of cholesterol was determined using gas -liquid chromatography as described earlier (44) .
Histology and Immunohistochemistry
WT, APP-Tg, Dhet, Npc-null and ANPC mice of 4, 7 and 10 weeks (n ¼ 4 -5 per genotype/age group) were transcardially perfused and fixed in 4% paraformaldehyde. Brains were sectioned on a cryostat (20 mm) and then processed as described earlier (5) . To determine cholesterol accumulation, brain sections from all five genotypes were incubated with 25 mg/ml of filipin in phosphate buffered saline for 30 min in the dark under agitation (5). For immunohistochemistry, sections were incubated overnight at 48C with the anti-GFAP, anti-Iba1, anti-CNPase, anti-Calbindin-D-28k, anti-cleaved caspase-3 or anti-Tau, caspase cleaved antibodies at dilutions listed in Table 1 . Subsequently, sections were incubated with appropriate HRP-conjugated secondary antibodies (1:400) for enzyme-linked immunohistochemistry or Alexa Fluor 488/594-conjugated secondary antibodies (1:1000) for immunofluorescence methods. Immunostained sections were examined and photographed using a Zeiss Axioskop-2 microscope (Carl Zeiss Canada Ltd.).
Neuronal cell counting
For neuronal quantification, every sixth section from the hippocampus and cerebellum of 7-week-old mice of different genotypes were used (n ¼ 3 to 4 per genotype). Hippocampal sections were stained with NeuroTrace 530/616 red fluorescent Nissl stain (1:300), whereas cerebellar Purkinje cells were labeled using anti-calbindin D-28k antiserum as mentioned above. Cell counts were normalized to the CA1 area or the Purkinje layer length and expressed as neuronal density as described earlier (51) .
Western blotting
Hippocampal and cerebellar brain regions were homogenized in ice-cold RIPA lysis buffer and protein content was determined using a BCA protein assay kit as described earlier (5) . Equal amounts of protein samples were separated on 4 -20% TrisGlycine gels or 4-12% NuPAGE Bis-Tris gels and transferred to nitrocellulose membranes, blocked with 5% non-fat milk and then incubated overnight at 48C with either anti-APP, anti-NPC1, anti-GFAP, anti-Iba1, anti-CNPase, anti-PSD95, anti-synaptophysin, anti-cathepsin D, anti-AT100, anti-PHF1, anti-AT8, anti-AT180, anti-AT270, anti-Tau-5, anti-Tau-1, anti-Tau, caspase cleaved, anti-phospho-Thr 202 /Tyr 204 ERK1/2, anti-ERK1/2, anti-Cdk5, anti-p35, anti-phospho-Tyr 216 GSK3 or anti-total GSK-3b antisera at dilutions listed in Table 1 . On the following day, membranes were washed, incubated with appropriate HRP-conjugated secondary antibodies (1:5000) and immunoreactive proteins were visualized using an ECL detection kit. All Blots were re-probed with anti-b-actin antibody and quantified using a MCID image analyzer.
Cathepsin D activity assay
Hippocampus and cerebellum of 7-week-old WT, APP-Tg, Dhet, Npc-null and ANPC mice (n ¼ 4 -8 per genotype) were homogenized and centrifuged at 48C for 10 min. The supernatant was assayed to determine the protein content and then used to measure the cathepsin D activity using the fluorogenic assay kit according to the manufacturer's instructions.
Subcellular fractionation
Hippocampus and cerebellum of 7-week-old WT, APP-Tg, Dhet, Npc-null and ANPC mice (n ¼ 3 -4 per genotype) were homogenized in ice-cold PBS and fractionated using the Qproteome cell compartment kit into cytosol, membrane and nuclear fractions. The protein content of different fractions was determined using a BCA protein assay kit and equal amounts of protein were separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE). Immunoblotting was performed with anti-cathepsin D, anti-cytochrome c, anti-Bax and anti-AIF antisera as mentioned earlier (44) . All blots were re-probed with anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH), anti-N-cadherin and anti-histone antibodies to check for equal protein loading for the cytosolic, membrane and nuclear fractions, respectively.
2-HPC treatment
A subset of WT, Npc-null and ANPC mice were administered a single subcutaneous injection of either 2-HPC (4000 mg/kg body weight; 20% wt/vol in saline solution; n ¼ 14-16 per genotype) or normal saline (n ¼ 9 -12 per genotype) at 7 days of age at the scruff of the neck as described recently (34) . Following treatment, a subset of mice from saline-and 2HPC-treated groups were kept to determine their longevity, whereas another subgroup were tested for object recognition memory and rotarod performance using protocols described above. In parallel, brains from saline-and drug-treated mice were collected and processed for histology, immunohistochemistry or immunoblotting as described above.
Statistical analysis
All data are presented as means + SEM. Statistical differences between the different genotype combinations were tested using one-way ANOVA followed by Newman -Keuls multiple comparison post-hoc analysis (Graph-Pad Software, Inc.) with significance set at P , 0.05. Differences among survival curves were determined using the log-rank test, whereas statistical differences between saline-and 2-HPC-treated Npc-null or ANPC mice were tested using the unpaired Student's t-test with significance set at P , 0.05.
